What kind of medicine does Deflazacort belong to?

Deflazacort is an oral glucocorticoid drug, a synthetic derivative of glucocorticoids, which improves muscle function by regulating immune responses and anti-inflammatory effects. It is mainly used to treat patients with Duchenne Muscular Dystrophy (DMD) and is suitable for children and adolescents aged 2 years and above. This type of drug cannot cure Duchenne muscular dystrophy, but it can delay muscle damage, improve muscle strength, slow down the progression of the disease, and provide patients with longer independent mobility and quality of life.

The mechanism of action of deflazacort mainly includes inhibiting the activation of inflammatory cells and the release of inflammatory mediators, thereby reducing chronic muscle fiber damage and necrosis. At the same time, it can improve protein metabolism and slow down muscle protein breakdown. Compared with traditional glucocorticoids such as prednisone and prednisolone, deflazacort has a relatively lower risk of side effects during long-term use, such as a smaller risk of weight gain, osteoporosis, and dysglycemia, which gives it a clear advantage in the long-term management of children.

Clinically, the use of deflazacort needs to strictly follow the guidance of a doctor and develop an individualized dosage plan based on weight, age and condition. During treatment, blood pressure, blood sugar, bone density, and growth and development indicators need to be monitored regularly to ensure the safety of medication, while potential adverse reactions are discovered and the dosage is adjusted in a timely manner. Patients and their families should closely cooperate with medical staff during use, maintain medication compliance, and pay attention to drug storage and daily safety management.

The introduction of deflazacort not only enriches the treatment options for Duchenne muscular dystrophy, but also provides patients with a more scientific and standardized long-term management plan. When used and monitored properly, deflazacort can significantly improve muscle strength, delay the progression of disability, and provide patients with a higher quality of daily life and longer ability to move independently.

Reference: https://www.drugs.com/mtm/deflazacort.html